The Board of Directors of Phoenix Solutions is pleased to announce that the company has signed an agreement with GE Healthcare AS (Norway) “GE” for supply of ACT® drug product for the upcoming planned clinical trials. CEO Per Sontum; “We are excited to sign this agreement and get GE on board as contract manufacturer of our product. With more than 20 years of experience producing Sonazoid™ and Optison®, GE`s Oslo organisation is the world leading site for the manufacturing of this class of pharmaceuticals.” GE`s General Manager for Norway, Bjørn Fuglaas comments: “We are very pleased that Phoenix has chosen to work with GE for this project, which is in line with the expectations we had when the company was spun out of GE in 2013. This is an area of interest and we believe GE to be uniquely positioned in this field given existing and strong capabilities within production of disperse pharmaceuticals, and microbubbles in particular ”. This will provide Phoenix Solutions with GMP ACT® drug product for clinical trials and ensure a way forward for supply of ACT® for commercialization.
For more information, please visit Phoenix Solutions website at www.phoenixsolutions.no